Back to top

cell-therapy: Archive

Zacks Equity Research

FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow

FATE reports a lower-than-expected loss on higher revenues and lower operating expenses in the second quarter of 2024.

FATEPositive Net Change KRYSPositive Net Change TRDAPositive Net Change

Zacks Equity Research

Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View

Iovance (IOVA) reports better-than-expected second-quarter results. Shares price rises on the back of encouraging product revenue guidance issued by management for 2024 and 2025.

IOVAPositive Net Change FULCPositive Net Change IMTXNo Net Change TRDAPositive Net Change

Zacks Equity Research

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2

Allogene's (ALLO) second-quarter earnings beat estimates but sales miss the mark. It expects to submit a regulatory filing with the FDA for its lead pipeline drug in large B-cell lymphoma indication by 2027.

ALLOPositive Net Change FULCPositive Net Change IMTXNo Net Change TRDAPositive Net Change